Index S&P 500
P/E 20.81
EPS (ttm) 7.45
Insider Own 0.50%
Shs Outstand 112.00M
Perf Week -1.49%
Market Cap 17.30B
Forward P/E 15.94
EPS next Y 9.73
Insider Trans -18.15%
Shs Float 111.06M
Perf Month -3.46%
Income 838.00M
PEG 3.20
EPS next Q 2.19
Inst Own 89.54%
Short Float 1.84%
Perf Quarter -0.87%
Sales 9.54B
P/S 1.81
EPS this Y 2.17%
Inst Trans 0.35%
Short Ratio 2.53
Perf Half Y 12.44%
Book/sh 60.79
P/B 2.55
EPS next Y 9.30%
ROA 5.67%
Short Interest 2.04M
Perf Year 9.84%
Cash/sh 6.84
P/C 22.64
EPS next 5Y 6.50%
ROE 12.66%
52W Range 123.04 - 165.32
Perf YTD 12.42%
Dividend Est. 2.92 (1.88%)
P/FCF 16.91
EPS past 5Y 7.36%
ROI 6.45%
52W High -6.24%
Beta 0.89
Dividend TTM 2.96 (1.91%)
Quick Ratio 1.17
Sales past 5Y 4.86%
Gross Margin 31.74%
52W Low 25.98%
ATR (14) 2.82
Dividend Ex-Date Jan 14, 2025
Current Ratio 1.25
EPS Y/Y TTM 11.04%
Oper. Margin 14.15%
RSI (14) 38.95
Volatility 2.03% 1.76%
Employees 48000
Debt/Eq 1.02
Sales Y/Y TTM 2.60%
Profit Margin 8.78%
Recom 2.14
Target Price 171.13
Option/Short Yes / Yes
LT Debt/Eq 0.91
EPS Q/Q 1.79%
Payout 37.76%
Rel Volume 0.77
Prev Close 156.07
Sales Surprise 2.39%
EPS Surprise 1.60%
Sales Q/Q 8.41%
Earnings Oct 22 BMO
Avg Volume 807.24K
Price 155.00
SMA20 -3.31%
SMA50 -0.84%
SMA200 6.80%
Trades
Volume 623,853
Change -0.69%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-10-24 Resumed
Jefferies
Buy
$175 → $185
Oct-23-24 Upgrade
Robert W. Baird
Neutral → Outperform
$157 → $182
Aug-28-24 Resumed
Evercore ISI
In-line
$165
Jul-10-24 Upgrade
Citigroup
Neutral → Buy
$145 → $165
Feb-26-24 Initiated
Leerink Partners
Market Perform
$135
Feb-07-24 Upgrade
Jefferies
Hold → Buy
$140 → $155
Jan-03-24 Initiated
Barclays
Equal Weight
$145
Dec-12-23 Upgrade
BofA Securities
Neutral → Buy
$140 → $160
Jun-29-23 Initiated
Piper Sandler
Neutral
May-02-23 Downgrade
BofA Securities
Buy → Neutral
$166 → $148
Apr-03-23 Upgrade
Citigroup
Sell → Neutral
$125 → $142
Jan-23-23 Initiated
Evercore ISI
In-line
$159
Nov-17-22 Downgrade
Citigroup
Neutral → Sell
$145 → $125
Aug-22-22 Resumed
Morgan Stanley
Equal-Weight
$142
Apr-04-22 Downgrade
Citigroup
Buy → Neutral
$175 → $140
Feb-23-22 Downgrade
UBS
Buy → Neutral
$160 → $139
Feb-02-22 Downgrade
Jefferies
Buy → Hold
$135
Jan-28-22 Downgrade
Deutsche Bank
Buy → Hold
$190 → $129
May-04-21 Upgrade
UBS
Neutral → Buy
$135 → $158
Mar-12-21 Downgrade
Robert W. Baird
Outperform → Neutral
$137
Show Previous Ratings
Dec-03-24 09:50AM
08:23AM
Nov-28-24 05:30AM
Nov-21-24 11:30AM
Nov-20-24 02:44PM
(Investor's Business Daily)
12:00PM
Loading…
Nov-13-24 12:00PM
Nov-12-24 05:57PM
Oct-25-24 09:15AM
Oct-24-24 01:06AM
Oct-23-24 07:53AM
03:03AM
Oct-22-24 11:49PM
(Thomson Reuters StreetEvents) +6.85%
05:22PM
03:46PM
07:55AM
06:51AM
Loading…
06:51AM
(Associated Press Finance)
06:45AM
Oct-16-24 09:40AM
Oct-15-24 10:00AM
08:04AM
Oct-14-24 08:50AM
Sep-30-24 09:40AM
Sep-25-24 11:24AM
Sep-24-24 09:40AM
Sep-18-24 08:51AM
Sep-16-24 08:51AM
Sep-05-24 09:40AM
Aug-30-24 09:40AM
Aug-28-24 03:31PM
Aug-27-24 08:23AM
08:50AM
Loading…
Aug-26-24 08:50AM
08:31AM
Aug-23-24 07:53AM
Aug-22-24 11:30AM
10:35AM
09:15AM
Aug-21-24 08:55AM
Aug-19-24 08:07AM
Aug-16-24 06:33AM
Aug-15-24 06:13PM
09:05AM
07:32AM
Aug-14-24 07:04PM
09:40AM
Aug-13-24 11:24AM
08:55AM
Aug-12-24 08:51AM
Aug-11-24 07:37AM
Aug-05-24 09:15AM
Aug-01-24 06:48AM
Jul-29-24 09:40AM
08:03AM
Jul-26-24 01:04AM
Jul-25-24 06:45AM
Jul-24-24 07:47AM
03:24AM
12:21AM
(Thomson Reuters StreetEvents)
Jul-23-24 10:05AM
07:55AM
06:51AM
(Associated Press Finance)
06:45AM
Jul-18-24 09:00AM
08:00AM
07:30AM
Jul-17-24 09:50AM
06:00AM
Jul-16-24 09:15AM
Jul-15-24 08:35AM
06:17AM
Jul-14-24 12:58PM
12:57PM
Jul-12-24 09:37AM
Jul-11-24 10:55AM
Jul-10-24 08:58AM
Jul-08-24 06:06AM
Jul-04-24 11:15AM
04:12AM
Jul-03-24 08:45AM
Jun-27-24 09:43AM
06:45AM
Jun-26-24 04:03PM
08:35AM
Jun-21-24 11:06AM
Jun-19-24 03:00PM
Jun-18-24 08:58AM
Jun-12-24 11:15AM
Jun-11-24 07:57AM
Jun-10-24 12:30PM
Jun-06-24 10:15AM
Jun-05-24 12:10PM
May-31-24 04:08PM
May-29-24 12:20PM
May-23-24 11:30AM
May-21-24 03:15PM
01:15PM
May-16-24 04:15PM
08:41AM
05:44AM
05:41AM
May-15-24 05:54PM
(The Wall Street Journal)
Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PREVOZNIK MICHAEL E SVP & General Counsel Nov 29 '24 Option Exercise 86.63 35,146 3,044,698 73,624 Dec 02 04:43 PM PREVOZNIK MICHAEL E SVP & General Counsel Nov 29 '24 Sale 163.07 35,146 5,731,302 38,478 Dec 02 04:43 PM Doherty Catherine T. EVP, Regional Businesses Nov 27 '24 Option Exercise 103.57 33,103 3,428,478 101,515 Dec 02 04:41 PM Doherty Catherine T. EVP, Regional Businesses Nov 27 '24 Sale 162.99 33,103 5,395,484 68,412 Dec 02 04:41 PM PREVOZNIK MICHAEL E Officer Nov 29 '24 Proposed Sale 163.07 35,146 5,731,302 Nov 29 02:42 PM Doherty Catherine T. Officer Nov 27 '24 Proposed Sale 162.99 33,103 5,395,484 Nov 27 04:12 PM DEPPE MICHAEL J SVP, Corp. Controller & CAO Nov 06 '24 Option Exercise 68.66 18,755 1,287,634 53,696 Nov 07 05:21 PM DEPPE MICHAEL J SVP, Corp. Controller & CAO Nov 06 '24 Sale 154.05 18,755 2,889,123 34,941 Nov 07 05:21 PM KUPPUSAMY KARTHIK SVP, Clinical Solutions Oct 28 '24 Sale 156.92 1,775 278,525 9,734 Oct 30 04:26 PM KUPPUSAMY KARTHIK Officer Oct 28 '24 Proposed Sale 156.87 1,775 278,450 Oct 28 12:51 PM PREVOZNIK MICHAEL E SVP & General Counsel Aug 29 '24 Option Exercise 95.80 32,551 3,118,223 71,029 Sep 03 04:30 PM PREVOZNIK MICHAEL E SVP & General Counsel Aug 29 '24 Sale 154.97 32,551 5,044,516 38,478 Sep 03 04:30 PM KUPPUSAMY KARTHIK SVP, Clinical Solutions Aug 28 '24 Sale 153.26 1,990 304,990 11,459 Aug 29 04:45 PM PREVOZNIK MICHAEL E Officer Aug 29 '24 Proposed Sale 154.97 32,551 5,044,516 Aug 29 01:55 PM KUPPUSAMY KARTHIK Officer Aug 28 '24 Proposed Sale 153.26 1,990 304,990 Aug 28 04:49 PM DELANEY MARK E SVP & Chief Commercial Officer Jul 24 '24 Sale 143.08 420 60,094 5,019 Jul 26 06:33 PM KUPPUSAMY KARTHIK SVP, Clinical Solutions Apr 29 '24 Sale 140.00 1,760 246,400 13,435 May 01 04:26 PM Doherty Catherine T. EVP, Regional Businesses Feb 28 '24 Sale 126.57 5,557 703,349 69,599 Mar 01 04:51 PM Doherty Catherine T. EVP, Regional Businesses Feb 29 '24 Sale 125.88 1,187 149,420 68,412 Mar 01 04:51 PM PREVOZNIK MICHAEL E SVP & General Counsel Feb 29 '24 Sale 125.88 5,611 706,313 38,478 Mar 01 04:50 PM PREVOZNIK MICHAEL E SVP & General Counsel Feb 22 '24 Sale 126.14 661 83,379 40,206 Feb 23 04:35 PM Gregg Vicky B Director Feb 23 '24 Sale 126.64 2,500 316,596 16,329 Feb 23 04:34 PM Doherty Catherine T. EVP, Regional Businesses Feb 22 '24 Sale 126.14 821 103,561 70,800 Feb 23 04:32 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite